Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy. Pediatr Blood Cancer 2020 May;67(5):e28249
Date
03/12/2020Pubmed ID
32159278Pubmed Central ID
PMC8396063DOI
10.1002/pbc.28249Scopus ID
2-s2.0-85081922982 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). However, this new paradigm has introduced unique considerations specific to the patients receiving CAR T-cell therapy, including prognostic uncertainty, symptom management, and psychosocial support. With increasing availability, there is a growing need for evidence-based recommendations that address the specific psychosocial needs of the children who receive CAR T-cell therapy and their families. To guide and standardize the psychosocial care offered for patients receiving CAR T-cell therapy, we propose the following recommendations for addressing psychosocial support.
Author List
Steineck A, Wiener L, Mack JW, Shah NN, Summers C, Rosenberg ARAuthor
Angela S. Steineck MD Assistant Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
ChildHumans
Immunotherapy, Adoptive
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
